ArticleFrontiers in pharmacology2025
Use of over-the-counter antiallergic products-analysis of sales data in Poland from 2020 to 2023.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study aimed to analyse purchasing trends of pharmacological products used in allergy management based on data from in-person pharmacy sales across Poland. Materials and Methods: The research involved an analysis of the sales of pharmacological agents used to alleviate symptoms of localized and systemic allergic skin reactions. The data were collected from a nationwide sample of 6,500 brick-and-mortar pharmacies over the period from 2020 to 2023. The analysis focused exclusively on over-the-counter (OTC) products. Results: Sales data were classified into three main groups: general antiallergic agents, antipruritic preparations, and products for relief after insect bites or stings. During the observation period, a total of 63.7 million units of allergy-relief products were sold. Conclusion: OTC antiallergic medications are widely used, with annual sales reaching millions of units. A clear seasonal trend was observed, with increased purchases during spring and summer months, coinciding with peak allergy seasons. Economic conditions such as inflation appeared to have minimal impact on OTC allergy product sales, likely due to their relatively low cost and high accessibility. Year-to-year purchasing trends remained stable throughout the study period. These findings may support more effective seasonal planning of OTC stock in pharmacies and inform public health initiatives aimed at allergy education and prevention. The stable demand also provides a basis for improving supply chain logistics and forecasting models related to allergy self-management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.